1-1-12 Wash-in for Desflurane Low Flow Anesthesia

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02013882

Enrollment

106

Registered

2013-12-17

Start date

2014-01-31

Completion date

2014-01-31

Last updated

2014-02-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anesthesia

Keywords

low flow anesthesia, wash-in, desflurane

Brief summary

We propose a new wash-in technique for desflurane low flow anesthesia with fresh gas flow of O2:N2O 1:1 L/min with desfluraene 12%. The objective of this study is to identify time to achieve alveolar concentration of desflurane at1, 2, 3, 4, 5 and 6%.

Detailed description

The benefits of low flow anesthesia are economic, less pollution, more heat and humidity preservation but it requires appropriate wash-in phase. The current wash-in protocols are complicated and time consuming. We propose a new 1-1-12 desflurane wash-in protocol which is more simple and predictable. The objective of this study is to identify time to achieve alveolar concentration of desflurane at 1, 2, 3, 4, 5 and 6% with 1-1-12 wash-in protocol. All patients will receive iv propofol 2 mg/kg as induction agent and succinyl choline 1.5 mg/kg for intubation. Then the ventilation will be controlled to achieve end-tidal CO2 30-35 mmHg with O2:N2O 1:1 L/min with desflurane 12%. Time to achieve alveolar concentration of desflurane at 1, 2, 3, 4, 5 and 6% will be recorded and analyzed. After that, the concentration of desflurane and anesthetic technique will be adjusted to requirement of anesthesiologist.

Interventions

PROCEDURE1-1-12 wash-in

wash-in phase during start of low flow anesthesia

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 64 Years

Healthy volunteers

Yes

Inclusion criteria

* ASA classification I-II * age 18-64 years

Exclusion criteria

* BMI \> 35 * contraindicated for N2O * with pulmonary or cardiac disease

Design outcomes

Primary

Measure	Time frame
Time (in second) to achieve alveolar concentration of desflurane 1, 2, 3, 4, 5 and 6%	participants will be followed until alveolar concentration of desflurane reaches 6%, as expected of 15 minutes

Secondary

Measure	Time frame
Heart rate	participants will be followed until alveolar concentration of desflurane reaches 6%, as expected of 15 minutes

Countries

Thailand

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026